Company Profile

AcuraStem Inc (AKA: AS)
Profile last edited on: 11/27/2023      CAGE: 7KRR1      UEI: EHEBD1K16MJ4

Business Identifier: Advanced cellular reprogramming/AI technologies: transforming standard care for neurodegenerative diseases through patient-specific treatment.
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

605 East Huntington Drive Suite 103
Monrovia, CA 90016
   (213) 290-0635
Location: Single
Congr. District: 31
County: Los Angeles

Public Profile

Led by experts in disease modeling, machine learning and drug development, as a company AcuraStem Inc is usefully understood as a patient-based drug discovery platform company developing novel drug programs for neurodegenerative diseases. Led and managed by experts in disease modeling, machine learning and drug development, the firm’s iNeuroRx®'s technology platform combines patient-derived disease models with human genetic data. Employing the latest scientific breakthroughs to address the most challenging - but tractable - of today's health problems to include amyotrophic lateral sclerosis (ALS). The firm's best-in-class technology platform consists of complex cellular models from ALS patient cells and sophisticated assays which permit AcuraStem’s scientists to model patient tissues in the lab. Using this ground-breaking technology, small molecule or gene targeting libraries canbe screened to discover the most efficacious therapeutic opportunities. AcuraStem’s iNeuroRx® platform is a breakthrough disease modeling platform, leveraging neurons derived from patients and advanced machine learning to discover therapeutic opportunities that rescue healthy motor neurons in those affected by neurodegenerative diseases, like ALS and FTD (frontotemporal dementia). AcuraStem has found unique therapeutic targets that work broadly for many types of ALS patients. Therefore, AcuraStem is developing PIKFYVE target therapeutics for ALS and FTD. Its most advanced drug candidate, AS-202, is in IND-enabling toxicity studies.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Samuel V Alworth -- Founder and CEO

  Justin Ichida -- President and Founder

  Paul August -- Founder

  Wen-Hsuan Chang

  Qing Liu -- Founder

  Steven Kyle Schlosser